BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.9639
-0.0961 (-9.07%)
At close: Nov 20, 2026, 4:00 PM EST
0.9900
+0.0261 (2.71%)
After-hours: Nov 20, 2026, 7:30 PM EST
BioLineRx Employees
As of December 31, 2025, BioLineRx had 24 total employees, including 20 full-time and 4 part-time employees. The number of employees decreased by 4 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
-4
Growth (1Y)
-14.29%
Revenue / Employee
$58,000
Profits / Employee
-$291,208
Market Cap
8.93M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | -4 | -14.29% | 20 | 4 |
| Dec 31, 2024 | 28 | -51 | -64.56% | 24 | 4 |
| Dec 31, 2023 | 79 | 30 | 61.22% | 79 | 0 |
| Dec 31, 2022 | 49 | 11 | 28.95% | 49 | 0 |
| Dec 31, 2021 | 38 | 0 | - | 38 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| aTyr Pharma | 60 |
| CytoMed Therapeutics | 42 |
| Palatin Technologies | 25 |
| Jasper Therapeutics | 22 |
| Lisata Therapeutics | 21 |
| IN8bio | 20 |
| BioVie | 13 |
| CalciMedica | 12 |
BLRX News
- 3 days ago - BioLineRx Ltd. Enters into $5.6 Million Royalty Monetization Transaction - Nasdaq
- 3 days ago - BioLineRx to Report Third Quarter 2026 Results on November 23, 2026 - PRNewsWire
- 3 days ago - BioLineRx enters $5.6M royalty monetization deal with Soleus Capital - TheFly
- 3 days ago - BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital - PRNewsWire
- 5 days ago - BioLineRx Ltd. and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates at SNO 2026 - Nasdaq
- 5 days ago - BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026 - PRNewsWire
- 4 weeks ago - BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 - PRNewsWire
- 6 weeks ago - BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day - PRNewsWire